Minerva Neurosciences, Inc. (NERV)
Largest Insider Buys in Sector
NERV Stock Price History Chart
NERV Stock Performance
About Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import …
Insider Activity of Minerva Neurosciences, Inc.
Over the last 12 months, insiders at Minerva Neurosciences, Inc. have bought $0 and sold $0 worth of Minerva Neurosciences, Inc. stock.
On average, over the past 5 years, insiders at Minerva Neurosciences, Inc. have bought $20,790 and sold $137,801 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,000 shares for transaction amount of $20,790 was made by VAN HEEK G JAN (director) on 2020‑09‑10.
List of Insider Buy and Sell Transactions, Minerva Neurosciences, Inc.
| 2023-05-02 | Sale | CEO | 3,641 0.0559% | $3.76 | $13,690 | +44.22% | ||
| 2023-05-01 | Sale | CEO | 23,753 0.4554% | $3.85 | $91,449 | +76.06% | ||
| 2023-05-01 | Sale | President | 22,082 0.4234% | $3.85 | $85,016 | +76.06% | ||
| 2023-05-01 | Sale | SVP, CFO and Secretary | 3,580 0.0799% | $4.48 | $16,038 | +76.06% | ||
| 2021-12-01 | Sale | director | 55,635 0.1267% | $0.88 | $48,959 | -24.75% | ||
| 2020-12-16 | Sale | EVP, CFO & CBO | 6,190 0.0149% | $2.64 | $16,342 | -10.31% | ||
| 2020-12-16 | Sale | CEO | 1,300 0.0031% | $2.64 | $3,432 | -10.31% | ||
| 2020-12-16 | Sale | SVP & Chief Operating Officer | 3,228 0.0078% | $2.64 | $8,522 | -10.31% | ||
| 2020-12-16 | Sale | SVP, Chief Accounting Officer | 1,845 0.0044% | $2.64 | $4,871 | -10.31% | ||
| 2020-09-10 | director | 7,000 0.0171% | $2.97 | $20,790 | -0.86% | |||
| 2020-05-26 | Sale | SVP, Chief Accounting Officer | 8,339 0.0216% | $15.00 | $125,085 | -78.03% | ||
| 2019-12-17 | Sale | EVP, CFO & CBO | 5,826 0.0152% | $7.10 | $41,365 | -46.98% | ||
| 2019-12-17 | Sale | CEO | 2,412 0.0063% | $7.10 | $17,125 | -46.98% | ||
| 2019-12-17 | Sale | SVP & Chief Operating Officer | 2,724 0.0071% | $7.10 | $19,340 | -46.98% | ||
| 2019-12-17 | Sale | SVP, Chief Accounting Officer | 1,557 0.0041% | $7.10 | $11,055 | -46.98% | ||
| 2019-12-12 | Sale | President | 3,113 0.0078% | $7.42 | $23,098 | -50.13% | ||
| 2019-06-27 | director | 3,500 0.009% | $5.50 | $19,250 | +23.53% | |||
| 2019-06-26 | director | 10,000 0.0264% | $5.55 | $55,500 | +25.05% | |||
| 2019-06-26 | director | 10,000 0.0255% | $5.37 | $53,700 | +25.05% | |||
| 2019-06-26 | director | 10,000 0.0266% | $5.60 | $56,000 | +25.05% |
Insider Historical Profitability
| Ollier Michele | 4488272 64.1786% | $2.10 | 2 | 1 | <0.0001% | |
| De Rubertis Francesco | 4488272 64.1786% | $2.10 | 2 | 1 | <0.0001% | |
| Index Venture Associates III Ltd | 10 percent owner | 3899189 55.7552% | $2.10 | 2 | 18 | <0.0001% |
| JOHNSON & JOHNSON | 10 percent owner | 3892256 55.6561% | $2.10 | 2 | 0 | <0.0001% |
| Pellegrini Lorenzo | 3883212 55.5267% | $2.10 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Federated Hermes | $3.49M | 19.32 | 1.35M | 0% | +$0 | 0.01 | |
| The Vanguard Group | $650,315.00 | 3.6 | 252,060 | +22.86% | +$121,017.52 | <0.0001 | |
| Renaissance Technologies | $459,000.00 | 2.54 | 177,765 | +65.83% | +$182,203.11 | <0.01 | |
| Ubs Oconnor Llc | $257,082.00 | 1.43 | 99,644 | +54.14% | +$90,300.17 | 0.01 | |
| BlackRock | $187,486.00 | 1.04 | 72,669 | 0% | +$0 | <0.0001 |